argenex (NASDAQ:ARGX) vs. TScan Therapeutics (NASDAQ:TCRX) Head-To-Head Contrast

TScan Therapeutics (NASDAQ:TCRX) and argenex (NASDAQ:ARGX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Risk & Volatility

TScan Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, argenex has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.

Profitability

This table compares TScan Therapeutics and argenex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
argenex	32.19%	43.59%	36.66%

Institutional and Insider Ownership

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 6.2% of TScan Therapeutics shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for TScan Therapeutics and argenex, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	5	2	0	2.12
argenex	0	6	23	1	2.83

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 1,054.40%. argenex has a consensus target price of $1,151.95, suggesting a potential upside of 40.63%. Given TScan Therapeutics’ higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than argenex.

Earnings & Valuation

This table compares TScan Therapeutics and argenex”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32 million	1.52	-$129.77 million	($0.91)	-0.25
argenex	$5.23 billion	9.80	$1.29 billion	$26.04	31.46

argenex has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Summary

argenex beats TScan Therapeutics on 11 of the 15 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.